AIDS Research Today is a free monthly online journal that collates and summarizes the latest research about AIDS, including details on testing, treatment, prevention, hiv, life expectancy.

Investigational agents for treatment of AIDS-related Kaposi's sarcoma.

Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

AIDS-related Kaposi's sarcoma (KS) is a neoplasm that results from the co-infection of HIV and KS herpesvirus/human herpesvirus-8 (KSHV/HHV8). Targeting HIV with highly active antiretroviral therapy has attenuated the natural history of this disease. Recent discoveries have elucidated the role of multiple signaling pathways in the pathogenesis of AIDS-related KS. In particular, KSHV/HHV8-specific gene products, including a G-protein-coupled receptor (vGPCR) and a homolog of human IL-6 (vIL-6), have been implicated in the development of tumorigenesis and angiogenesis. In addition, KSHV/HHV8 can modulate cellular growth and angiogenic pathways to augment malignant transformation and potentiate growth. This article discusses the main signaling pathways that are implicated in the pathogenesis of AIDS-related KS, reviews recently completed clinical trials and anticipates the future direction of molecularly targeted agents in this disease.

Published 20 March 2007 in Expert Opin Investig Drugs, 16(4): 495-504.
Full-text of this article is available online (may require subscription).

© 2004-2009 AIDS Research Today. All Rights Reserved.